Benjamin A. Derman

Jul 31, 2023 | jamanetwork.com | Benjamin A. Derman |William Parker

The treatment landscape for relapsed/refractory multiple myeloma has undergone an immunotherapeutic breakthrough with the introduction of 2 commercial B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapies for patients with heavily pretreated relapsed/refractory multiple myeloma: idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti).1,2 These therapies have led to durable responses and significantly reduced the risk of progression or...